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Background and purpose: Chronic inflammatory conditions, such as granulomas, are associated with angiogenesis. Mast cells
represent the main cell type orchestrating angiogenesis, through the release of their granule content. Therefore, compounds
able to modulate mast cell behaviour may be considered as a new pharmacological approach to treat angiogenesis-dependent
events. Here, we tested the effect of selective cannabinoid (CB) receptor agonists in a model of angiogenesis-dependent
granuloma formation induced by l-carrageenin in rats.
Experimental approach: Granulomas were induced by l-carrageenin-soaked sponges implanted subcutaneously on the back
of male Wistar rats. After 96 h, implants were removed and granuloma formation was measured (wet weight); angiogenesis
was evaluated by histological analysis and by the measurement of haemoglobin content. Mast cells in the granulomas were
evaluated histologically and by RT-PCR and immunoblotting analysis for mast cell-derived proteins (rat mast cell protease-5
(rMCP-5) and nerve growth factor). Selective CB1 and CB2 receptor agonists, ACEA and JWH-015 (0.001–0.1 mg mL
1), were
given locally only once, at the time of implantation.
Key results: The CB1 and CB2 receptor agonists decreased the weight and vascularization of granulomas after 96 h. This
treatment also reduced mast cell number and activation in granulomatous tissue. Specifically, these compounds prevented the
transcription and expression of rMCP-5, a protein involved in sprouting and advance of new blood vessels.
Conclusion and implications: Modulation of mast cell function by cannabinoids reduced granuloma formation and associated
angiogenesis. Therefore cannabinoid-related drugs may be useful in the management of granulomatous diseases accompanied
by angiogenesis.
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Introduction
Angiogenesis, the process leading to new vessel formation
from the pre-existing vessels, is involved both in physiological
and pathological conditions, such as rheumatoid arthritis,
diabetic retinopathy and tumour growth. During chronic
inflammation, angiogenesis occurs for the maintenance of
tissue perfusion and to allow the increase in cellular trafficking
necessary for chronicity (Colville-Nash et al., 1995).
Several experimental models, both in vitro and in vivo, have
been used to characterize the mechanisms involved in new
blood vessel formation and associated cell trafficking, to
develop drugs and strategies to control or prevent the
pathological consequences. The subcutaneous implantation
of l-carrageenin-soaked sponges on the back of rats induces a
chronic response, characterized by granuloma formation and
including an intense angiogenesis and infiltration of inflam-
matory cells (Lage and Andrade, 2000). Granulomatous
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tissue is histologically well-characterized by the presence of
infiltrating macrophages, epithelioid and giant cells, acti-
vated mast cells (MCs), surrounded by a lymphocyte mantle
and proliferating fibroblasts (Forehand and Johnston, 1994).
Among the cells participating in granuloma formation,
connective tissue type MCs, especially present in the skin,
importantly contribute to the development of chronic
inflammation. MCs, which have been shown to accumulate
near sites of new capillary sprouting, have been implicated in
angiogenesis; in fact they produce, store and release several
mediators, both vasoactive amines (Metcalfe et al., 1997) and
enzymes to degrade the connective tissue matrix, thus
providing space for neovascular sprouts (Ka¨ha¨ri and
Saarialho-Kere, 1997; Tozzi et al., 1998).
Among the mediators in MCs, the chymases, a family of
serine proteases exclusively expressed in connective tissue
MCs, represent interesting molecules exhibiting both pro-
inflammatory and pro-angiogenic activities (Coussens et al.,
1999). In humans and dogs, only a-chymases are present
(Takai et al., 1997), whereas mice and rats have several
chymase isoenzymes that belong to the a-chymase family
(mouse mast cell protease-5 and rat mast cell protease-5
(rMCP-5)) and the b-chymase family (mouse MCP-1,2,4 and
rMCP-1, 2, 4) (Reynolds et al., 1990; Lutzelschwab et al.,
1997).
Recently, cannabinoids have been described as a novel
class of antiangiogenic compounds, as they inhibit migra-
tion and survival of vascular endothelial cells (Bla´zquez et al.,
2004). Moreover, administration of cannabinoids to glioma-
bearing mice decreases the activity and the expression of
matrix metalloproteinase-2, a proteolytic enzyme that allows
tissue breakdown and remodelling during angiogenesis
trans-activation (Hart, 2004).
Most of the effects of the cannabinoids are mediated by
the activation of specific G protein-coupled receptors that
are normally bound by a family of endogenous ligands—the
endocannabinoids (Bisogno et al., 2005). Two different
receptors for CB compounds (Alexander et al., 2008) have
been characterized and cloned from mammalian tissues: the
CB1 receptors, mostly expressed in the nervous system and
responsible for CB psycho-activity (Pertwee, 1999), and the
CB2 receptors, mostly expressed in the immune system and
unrelated to CB psycho-activity (Matias et al., 2002).
However, the expression of both CB1 and CB2 receptors on
cells from the immune system has also been extensively
documented (Croxford and Yamamura, 2005). In the present
context, MCs express both CB1 and CB2 receptors, which
exhibit differential roles during IgE-dependent responses
(Samson et al., 2003). The endocannabinoid 2-arachydonoyl
glycerol, which preferentially binds to CB2 receptors,
decreases the immunological activation of guinea pig MCs
(Vannacci et al., 2004).
Although the effects of cannabinoids in angiogenesis-
dependent pathologies, especially that associated with
several tumour types (Blazquez et al., 2003; Casanova
et al., 2003) are well known (Kogan et al. 2006,
De Filippis et al. 2007), their role in MC-dependent
angiogenesis has never been studied. The aim of our
study was, therefore, to investigate the effect of synthetic
CB agonists as a new class of antiangiogenic agents,
focusing on their ability to control MC function and their
release of pro-angiogenic factors, in a model of granuloma
formation in rats.
Methods
Animals
All animal procedures and experiments were in accordance
with European Community Council Directive 86/609/EEC
and efforts were made to minimize animal suffering and to
reduce the number of animals used. Experiments using
animals were done with the permission of the national
authorities (Ministero della Salute Prot. 5/05 to Professor
Teresa Iuvone). Male Wistar rats (Harlan, Italy), weighing
220–250 g, were used in all experiments. Animals were
provided with food and water ad libitum. The light cycle
was automatically controlled (on 07 h 00 min; off 19 h
00 min) and the room temperature thermostatically regu-
lated to 22±1 1C with 60±5% humidity. Prior to the
experiments, animals were housed in these conditions for
3–4 days to become acclimatized.
Sponge implantation
Sponges were implanted as previously described by De
Filippis et al. (2007). Briefly, two polyether sponges
(0.51.52.0 cm) weighing 0.035±0.002 g were implanted
subcutaneously on the back of rats (n¼12–18 for each
group) under general anaesthesia. Sponges and surgical
instruments were sterilized by autoclaving for 20 min at
120 1C. l-carrageenin (1% w v1) (Sigma, St Louise, MI, USA)
was dissolved in pyrogen-free saline (500 mg in 0.5 mL per
implant), in presence or absence of CB agonists and injected
into each sponge; saline (0.5 mL per implant) was used as
control. Ninety-six hours after sponge implantation, rats
were killed by inhaling CO2.
Treatments
The non-selective CB1/CB2 full agonist WIN 55,212-2, a CB1
selective agonist, ACEA, or a CB2 selective agonist, JWH-015,
were given only once, at the time of sponge implantation,
together with the l-carrageenin. In some experiments,
ketotifen fumarate (0.1 mg mL1; equivalent to 50 mg per
implant), a mast cell stabilizer, was given similarly only at
implantation, as a positive control to prevent mast cell
degranulation. Three different concentrations of ACEA and
JWH-015 (0.001, 0.01 and 0.1 mg mL1; equivalent to 0.5, 5
and 50 mg per implant) were tested.
Collection of tissue, weight evaluation and homogenization
After death, implants and the adherent granulomas were
excised from the back of the rats. The granulomatous tissue,
that is, the newly formed tissue encapsulating the sponge,
was then dissected from the sponge and weighed always by
the same person who was unaware of the treatments. This
tissue was then immediately frozen in liquid nitrogen and
stored in sterile and RNAse free vials at 80 1C until used.
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For homogenization, tissue was suspended in ice-cold
hypotonic lysis buffer (20 mM HEPES, 100 mM MgCl2, 0.4 M
NaCl, 0.5 mM phenylmethylsulphonylfluoride, 15 mg mL1
soybean trypsin inhibitor, 3mg mL1 pepstatin A, 2 mg mL1
leupeptin, 40 mM benzamidine, 1 mM dithiothreitol, 1%
Nonidet P40, 20% glycerol) in a ratio of 0.4 mL per 100 mg
of tissue and homogenized at the highest setting for 2–5 min
in Polytron PT300 tissue homogenizer. Protein concentra-
tion was determined using the Bio-Rad protein assay kit.
Preparation of cytosolic fraction
After homogenization, the cytosolic fraction was obtained
by centrifugation for 1 min at 13 000 g. The nuclear pellet
was resuspended in 60 mL of high salt extraction buffer
(20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 25% v v1 glycerol, 0.5 mM phenylmethylsulphonyl-
fluoride, 1.5 mg mL1 soybean trypsin inhibitor, 7 mg mL1
pepstatin A, 5 mg mL1 leupeptin, 0.1 mM benzamidine,
0.5 mM dithiothreitol) and incubated with shaking at 4 1C
for 30 min. Protein concentration in cytosolic fractions was
determined by the Bio-Rad protein assay kit.
Evaluation of angiogenesis
Angiogenesis was evaluated both by histological investiga-
tions (Histology of granulomatous tissue) and by the
measurement of haemoglobin (Hb) content in the granulo-
matous tissue. For the evaluation of Hb content, the
granulomatous tissue was homogenized on ice with the
Polytron PT300 tissue homogenizer in 1 M PBS (4 mL g1 wet
weight) as previously described (De Filippis et al., 2007).
Briefly, after centrifugation at 2500 g for 20 min at 4 1C, the
supernatant was further centrifuged at 5000 g for 30 min and
Hb concentration in the supernatant was determined
spectrophotometrically at 450 nm by using the Hb assay kit
(Sigma Diagnostic, St Louise, MI, USA). The Hb content was
expressed as mg Hb g1 wet weight.
Western blot analysis
Western blotting analysis for r-MPC-5, nerve growth factor
(NGF) and tubulin proteins was performed on the total
protein fraction of homogenates of granulomatous tissue.
Total proteins were mixed with gel loading buffer (50 mM
Tris/10% SDS/10% glycerol 2-mercaptoethanol/2 mg bromo-
phenol in a final volume of 1 mL) in a ratio of 1:1 and boiled
for 3 min. Equivalent amounts (50 mg) of each sample were
analysed by electrophoresis through a 12% discontinuous
polyacrylamide minigel. Proteins were transferred onto
nitrocellulose membrane, according to the manufacturer’s
instructions (Bio-Rad, Segrate, Milano, Italy). The mem-
branes were saturated by incubation at 4 1C overnight with
10% non-fat dry milk in 1 M PBS and then incubated with the
appropriate antiserum: anti-mouse chymase antiserum
(1:250 v:v, NeoMarker, Fremont, CA, USA), anti-mouse
NGF (1:250 v:v, Sigma-Aldrich, St Louise, MI, USA), anti-
mouse tubulin (1:1000 v:v, Santa Cruz, Santa Cruz, CA, USA)
for 2 h at room temperature. The membranes were washed
three times with 1% Triton X-100 in PBS 1 M and then
incubated with anti-mouse immunoglobulins coupled to
peroxidase (Dako, Glostrup, Denmark) (1:2000 v:v). The
immune complexes were developed using enhanced chemi-
luminescence detection reagents (Amersham, Freiburg,
Germany), according to the manufacturer’s instructions
and exposed to Kodak X-Omat film. The protein bands on
X-ray film were scanned and densitometrically analysed with
a GS-700 imaging densitometer.
mRNA analysis
The r-MPC5 mRNA level in granulomatous tissue was
determined by using the semi-quantitative RT-PCR method.
Total RNA was extracted from tissue samples by using an
ultrapure TRIzol reagent (GibcoBRL, Carlsbad, CA, USA) as
directed by the manufacturer. RNA (5 mg) was then reverse-
transcribed in 20 mL with 200 U of Superscript II RNase H-
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) in the
presence of random hexamers (5 mM), 20 U of RNasin
(Promega, Milano, Italy), dNTPs (10 mM), for 1 h at 42 1C.
PCR was performed on 2mL of the reverse transcription
reaction mixture in a final volume of 50 mL with 2.5 U of Taq
polymerase (Roche, Milano, Italy) and 5mM of the appro-
priate primers as follows: rMCP-5 50-TCCTGCAAACACTTC
ACCAG-30 (forward primer) and 50-CGAGATCCAGAGTTAA
TTCT-30 (reverse primer); b-actin 50-GGCACCACACCTTCTA
CA-30 (forward primer) and 50-CAGGAGGAGCAATGATCT-30
(reverse primer). To obtain linear amplification curves, the
cDNA mixtures were subjected to 10, 15 and 20 cycles for the
control b-actin and 20, 25 and 30 cycles for all other genes
under the following conditions: denaturating at 95 1C for
1 min, annealing at 52 or 56 1C for 1 min for chymase
respectively, and extension at 72 1C for 1 min. The final
extension step was performed at 72 1C for 10 min. Aliquots
(15 mL) of PCR products were electrophoretically fractionated
through 1% agarose gel containing the fluorescent Vistra
green dye (Amersham Pharmacia Biotech, Freiburg,
Germany) (Mullane et al., 1985). Labelling intensity of the
PCR product, which is linear to the amount of DNA, was
quantified using the Molecular Imager FX and Quantity One
software (Bio-Rad).
Histology of granulomatous tissue
After excision of the implant, the granulomatous tissue
around the sponge was removed and fixed in 10% formalin.
Thin (0.5 mm) paraffin sections were prepared and stained
with toluidine blue according to Iuvone et al. (1999) and
then processed for light microscopy examination. Mast cells
were counted in five randomly selected sections using a
100 objective lens, differentiating between deep blue (un-
degranulated) and light blue (degranulated) MCs. In some
experiments, paraffin wax sections were cut at 4–6 mm and
stained with haematoxylin and eosin for the evaluation of
blood vessels. The same person counted the blood vessels in
different fields on at least three different stained sections of
the same group, but from different experiments.
b-Hexosaminidase analysis
Degranulation of MCs in granulomatous tissues was
measured by the release of the granular enzyme
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bhexosaminidase, using a method first described by
Hernandez-Hansen et al. (2004). Granulomatous tissue was
placed in 24-well culture plates and cultured in Dulbecco’s
modified Eagle’s medium supplemented with 5% foetal
bovine serum, 2 mM glutamine, 100 U mL1 penicillin,
100 mg mL1 streptomycin at 37 1C in 5% CO2/95% air for
24 h according to Coe¨ffier et al. (2002).
Aliquots (50 mL) of tissue culture medium were then
collected from each well and transferred into a 96-well plate.
The substrate, p-nitrophenyl N-acetyl-b-D-glucosaminide
(50 mL of a 2 mM solution diluted in 0.2 M citrate buffer, pH
4.5), was added to each well. The samples were then
incubated with the substrate for 2 h at 37 1C. All incubations
were carried out at this temperature because the reactions are
sensitive to temperature changes. Medium and chemicals
were also kept at 37 1C throughout the experiment to avoid
any temperature changes. After 2 h, reactions were termi-
nated by adding 150mL of 1 M Tris-buffer pH 9.0. The
absorbance was measured in a microplate reader at 405 nm.
The b-hexosaminidase content was also determined in
parallel wells where the cultured tissue was homogenized
in PBS. Mast cell degranulation was expressed as percentage
of b-hexosaminidase release, calculated as the ratio between
b-hexosaminidase released into the supernatant and
the total b-hexosaminidase content released from the
homogenate.
Data analysis
Results were expressed as the mean±s.e.m. of n animals
where each value is the average of responses in duplicate
sites. Statistical comparisons were made by one way-ANOVA
followed by Bonferroni’s test for multiple comparisons.
A P-value of less than 0.05 was considered to be significant.
Drugs
The non-selective CB1/CB2 full agonist WIN 55 2122,
(Ki¼62,3 and 3,3 nM at human cloned CB1 and CB2
receptors respectively), the potent and the highly selective
CB1 receptor agonist ACEA, (Ki¼1,4 nM for CB1 displays
41400-fold selectivity over CB2 receptors) and the selective
CB2 receptor agonist JWH-015 (Ki values are 13,8 and 383 nM
as measured at human cloned CB2 and CB1 receptors
expressed in CHO cells) were purchased from Tocris, Bristol,
UK and were dissolved in ethanol. A volume of 100 mL of
ethanol (0.01% v:v) did not affect the response under study.
All other materials unless otherwise stated were purchased
from Sigma Aldrich, Gallarate (Mi), Italy. Drug and mole-
cular target nomenclature follows the Guide to Receptors
and Channels (Alexander et al., 2008).
Results
Effect of the selective CB1 receptor agonist ACEA and selective CB2
receptor agonist JWH-015, on l-carrageenin-induced granuloma
formation and related angiogenesis
The selective CB1 and CB2 CB receptor agonists, ACEA and
JWH-015, applied locally in the sponge at the time of
implantation, decreased l-carrageenin-induced granuloma
formation in rats after 96 h of implantation (Figure 1a) This
reduction was dose-dependent and approximately equal for
the two agonists over the concentration range used (0.001–
0.1 mg mL1; 0.5–50 mg).
The selective agonists, ACEA and JWH-015, at their
highest dose (0.1 mg mL1; 50 mg), as well the non-selective
CB1/CB2 receptor agonist, WIN 55 212-2 (0.1 mg mL
1:
50 mg), significantly decreased neovascularization in the
granulomatous tissue, measured as Hb content, by 55, 47
and 58%, relative to the values obtained with l-carrageenin
alone. The vehicle (10% ethanol) had no effect on either the
weight of the granulomatous tissue or on its vascularization
(Figures 1a and b).
Effect of ACEA and JWH-015 on l-carrageenin induced-mast cell
activation in granulomatous tissue
Histological analysis of granulomatous tissue showed that
ACEA (50 mg) and JWH-015 (50 mg) reduced the total number
of MCs, by about 50% with respect to l-carrageenin alone
(Figure 2a; summarized in Figure 2b), but did not change the
proportion of degranulated MCs induced by l-carrageenin
(Figure 2c). In addition, l-carrageenin also increased
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Figure 1 Effect of the selective CB1 receptor agonist ACEA and the
selective CB2 receptor agonist JWH-015 on l-carrageenin (CAR)-
induced granuloma. (a) ACEA (0.5, 5, 50mg per implant) and JWH-
015 (0.5, 5, 50mg), significantly and in a concentration-dependent
manner reduced granulomatous tissue formation, evaluated as wet
weight at 96 h after implantation. (b) Local administration of ACEA
(50 mg) or JWH-015 (50mg) or the non-selective CB1/CB2 receptor
agonist, WIN 55,212-2 (WIN; 50mg), significantly reduced angio-
genesis, evaluated as haemoglobin (Hb) content of the granuloma.
No effects were observed in the group treated with vehicle (10%
ethanol;EtOH). Results are expressed as mean±s.e.m. of three
separate experiments. *Po0.05, ***Po0.001 vs saline; 11Po0.01,
111Po0.001 vs l-carrageenin alone.
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b-hexosaminidase release (as marker of degranulation) in the
granulomas, whereas the treatment with CB agonists did not
affect this process (Figure 2d). Ketotifen (50 mg), a well
known MC membrane stabilizer, used as positive control,
reduced hexosaminidase release in the carrageenin-soaked
sponge by 60% (Figure 2d).
Effect of ACEA and JWH-015 on levels of mRNA for rMCP-5
We have previously demonstrated that the amount of
rMCP-5, the most abundantly expressed chymase in the
skin (Wintroub et al., 1984) with pro-angiogenic effects, was
increased in the granulomatous tissue by l-carrageenin
treatment (Russo et al., 2005). As we have shown that
cannabinoids are able to reduce angiogenesis, we wondered
if the formation of new vessels was associated with a
modulation of rMCP-5 gene expression. To this purpose,
total RNA extracted from the granulomatous tissue 96 h after
sponge implants was subjected to semi-quantitative RT-PCR
by using specific primers for rMCP-5. We also amplified the
same preparation with oligonucleotides designed against
b-actin mRNA as control of cDNA amount. As shown in
Figure 3, levels of rMCP-5 mRNA were markedly higher in
the granulomatous tissue of l-carrageenin-soaked sponges.
After treatment with ACEA (50 mg) or JWH-015 (50 mg), this
induced increase was reduced by about 50% by either agonist
(Figure 3b).
Effect of ACEA and JWH-015 on l-carrageenin- induced
expression of rMCP-5 and NGF
Not only the transcription but also the expression of rMCP-5
protein in granulomatous tissue was affected by l-carragee-
nin treatment, as shown by immunoblotting and relative
densitometric analysis. The antibody used for rMCP-5 was
raised in mice and recognized rat chymase. Either ACEA or
JWH-015 significantly reduced rMCP-5 protein expression by
about 50%, compared with that after l-carrageenin alone
(Figure 4a). We also evaluated another specific MC-derived
protein, NGF. NGF protein expression was increased in l-
carrageenin-treated sponges as shown by western blot and
relative densitometric analysis. The same dose of ACEA or
JWH-015 (50 mg) reduced the expression of this marker
protein by 53 and 51%, respectively, compared with that in
sponges treated with l-carrageenin alone (Figure 4b).
Effect of ACEA and JWH-015 on vessel numbers in
granulomatous tissue
Histological analysis performed on haematoxylin–eosin
stained sections of granulomas showed that l-carrageenin
treatment markedly increased the number of vessels in the
tissue, compared with saline-treated sponges. ACEA or JWH-
015 (50 mg) significantly reduced, by 59 and 68% respec-
tively, the numbers of blood vessels, in comparison to those
in sections from sponges treated with l-carrageenin alone
(Figure 5).
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Figure 2 Effect of the selective CB1 receptor agonist ACEA (50 mg) and the selective CB2 receptor agonist JWH-015 (50 mg) on l-carrageenin
(CAR)-induced mast cell activation. In panel (a) is shown a representative histological analysis of mast cells present in granulomatous tissue.
Mast cells were evaluated in paraffin sections stained with 0.05% (w v1) toluidine blue and counterstained with 0.1% (w v1) nuclear fast red
(magnification 100). The square panel is an enlargement showing the differences between not degranulated (deep blue) and degranulated
(light blue) mast cells. In panel (b) is shown the total number of mast cells; in panel (c) the percentage of mast cell degranulation (the ratio
between not degranulated and degranulated mast cells) is shown; in panel (d) is shown the percentage of the bhexosaminidase release, as a
specific marker of mast cell degranulation. Ketotifen (KET; 50 mg) was used as a positive control. Results are expressed as mean±s.e.m. of three
separate experiments. *Po0.05, **Po0.01, ***Po0.001 vs saline; 111Po0.001 vs l-carrageenin alone.
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Discussion
Angiogenesis occurs both in physiological processes, such as
wound healing (Trabucchi et al., 1988) and placental
development (Augustin et al., 1995) and in many patholo-
gical conditions, including solid tumours (Folkman, 1995),
diabetic retinopathy (Mohamed et al., 2007), rheumatoid
arthritis (Malone et al., 1987) and other inflammatory
disorders (Hunt et al., 1984; Toda et al., 2000). The
importance of MCs in orchestrating the processes of
angiogenesis is now well recognized, as these cells are in
close proximity to blood vessels and release a plethora of pro-
angiogenic mediators. In the light of these findings, in the
present study we investigated the effect of cannabinoids in
preventing MC-dependent angiogenesis during granuloma
formation.
Our results show that selective CB1 and CB2 receptor full
agonists, respectively ACEA and JWH-015, given into the
sponge at the time of implantation, were able to control MC
function, resulting in a decreased growth of the granuloma
(wet weight) and decreased angiogenesis within the granu-
loma. These results are in accordance with previous results
from Facci et al. (1995) and our own recent data (Iuvone
et al., 2007), indicating that cannabinoids are able to control
MC activation through a mechanism which is mediated, at
least in part, by either CB1 or CB2 receptor activation. In the
present study, we did not counteract antiangiogenic effects
of ACEA and JWH-015 by selective antagonism of CB1 and
CB2 receptors, and we therefore cannot definitively exclude
non-CB receptor-mediated effects, especially for JWH-015
which exhibits other activities unrelated to CB2 receptors
(Velez-Pardo and Del Rio, 2006). On the other hand, it is well
known that cannabinoids control MC behaviour, mainly
through a CB2 receptor-dependent mechanism (for a review
see De Filippis et al. 2008).
Here, for the first time, we showed that both the selective
agonists, ACEA and JWH-015, reduced l-carrageenin-in-
duced increase of MC numbers in granulomatous tissue,
without affecting, in our conditions, the extent of MC
degranulation. In our experimental conditions, the effects of
cannabinoids on MC function were linked to the inhibition
of MC transcriptional machinery, as confirmed by RT-PCR
for rMCP-5. After treatment with ACEA and JWH-015, we
observed a significant downregulation (about 50%) of
rMCP-5 gene expression at transcriptional and, at
translational levels. We focused our study on rMCP-5 protein
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Figure 3 Effects of the selective CB1 receptor agonist ACEA and the
CB2 receptor agonist JWH-015 on rMCP-5 transcription and
expression. (a) Representative Vistra green-stained agarose gel of
RT-PCR products corresponding to rMCP-5 mRNA in sponges
injected with saline solution (SAL) or with l-carrageenin (CAR) or
l-carrageenin in the presence of ACEA (50mg) or JWH-0.15 (50 mg).
b-actin, a housekeeping gene, was used as a control. The gel shown
corresponds to the products from 35 cycles of amplification for
rMCP-5 and 15 cycles for b-actin. (b) Summary of values from three
independent experiments expressed as percent, after normalization
to b-actin mRNA level. Results are expressed as mean±s.e.m. of
three separate experiments. *Po0.05, ***Po0.001 vs saline.;
111Po0.001 vs l-carrageenin alone.
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Figure 4 Effects of the CB1 receptor agonist ACEA (50mg) and the CB2 receptor agonist JWH-015 (50mg) on expression of proteins secreted
by mast cells. In (A) rMCP-5 and (B) NGF protein expression is shown by a representative western blot (a) and relative densitometric analysis
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because it is the only protein stored and/or newly synthe-
sized exclusively by connective tissue MCs and for this
reason it could be considered as an index of MC function.
Our data highlighted that cannabinoids reduce not only the
transcription but also the expression of rMCP-5 protein in
granulomatous tissue. This enzyme, rMCP-5, belongs to the
chymase family and shares their functions in the angioge-
netic process. Chymases act as extracellular matrix degrading
enzymes, either by themselves or by the activation of
metalloproteinases (Johnson et al., 1998), facilitating in this
way the advance of blood vessels. Particularly, we have
previously demonstrated that, by blocking rMCP-5 with an
antisense oligonucleotide, specific for this chymase, it
was possible to prevent angiogenesis during granuloma
formation (Russo et al., 2005).
The evidence that cannabinoids affect MC was further
strengthened by the ability of ACEA and JWH-015 to reduce,
following l-carrageenin treatment, the expression of NGF,
another important mediator synthesized and released by
MC. In the experiments presented here, we were not able to
investigate, in more detail, the possibility that the decrease
in rMCP-5 and NGF levels was related to the decline in total
MC number. Our results suggest that cannabinoids, by
controlling MC function, may prevent, at least in part,
granuloma-associated angiogenesis. Here, we have shown
that selective CB1 and CB2 agonists significantly reduced
new vessel formation, both by histological analysis and by
the measurement of the Hb content in the tissue. Moreover
these results are compatible with our previous work
demonstrating pro-angiogenic effects of CB1 and CB2
receptor antagonists, in the same model (De Filippis
et al., 2007).
In conclusion, all the data reported here indicate that
ACEA and JWH-015 exhibit antiangiogenic properties, as
they were able to decrease neovascularization in the
granulomas, correlated with a reduction in MC number
and in MC granule-derived mediators (rMCP-5 and NGF),
without affecting the degranulation responses (hexosamini-
dase release). From our results, we would propose a
mechanism for the antiangiogenic effects of cannabinoids
in granulomas, which could include the effects on NF-kB
activation, previously demonstrated by us (De Filippis et al.,
2007), recognizing for the first time MCs as an important
cellular target of CB effects in our model.
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